TOBINintel · Condition
Type 2 Diabetes
Beta-cell stress is modeled as the end point of several drivers at once: glycemic load and nutrient quality, oxidative and mitochondrial stress, hormonal signaling, low-grade inflammation and selected exposures.
Key points
- Gut barrier function and bile-acid signaling are tracked as modifiers of glycemic control; detection of an organism is not treated as infection.
- Test to discuss: HbA1c, fasting glucose, OGTT where indicated
- Test to discuss: Fasting insulin and C-peptide
- Test to discuss: ApoB, lipids, urine albumin-creatinine ratio
- Test to discuss: Retinal and foot examination per guideline
- Carbohydrate quality and fiber targets
- Post-meal activity
- Weight reduction where indicated
- Annual screening in high-risk patients
Root-cause chain
O · Established causal · Glucotoxicity and lipotoxicity raise mitochondrial ROS and impair insulin secretion; reproduced across human and preclinical evidence.
I · Established causal · Cytokine-mediated interference with insulin receptor signaling in muscle and liver.
N · Observational association · Cofactor roles in glucose handling; intervention data are mixed and deficiency-dependent.
T · Observational association · Several cohorts report associations with incident diabetes; confounding and reverse causation are not excluded.
Protocols by lane
Evidence grade + regulatory statusGuideline-standard glucose lowering with long-term safety data.
Status: FDA-approved · Cautions: Avoid in advanced renal impairment; monitor B12, which metformin can deplete.
Improves time-in-range and dietary adherence.
Status: FDA-approved · Cautions: Avoid over-interpretation of single excursions.
Addresses a documented drug–nutrient depletion.
Status: Supplement · Cautions: Confirm deficiency; investigate macrocytosis and neuropathy properly.
Small trials suggest modest glycemic effects; not a substitute for therapy.
Status: Supplement · Cautions: Hepatotoxicity concerns with high-coumarin cassia cinnamon; interaction risk with anticoagulants.
Lowers HbA1c independently of weight change.
Status: Lifestyle · Cautions: Adjust insulin or sulfonylurea dosing to avoid hypoglycemia.
Preliminary and inconsistent symptom data only.
Status: Investigational · Cautions: Not a glucose-lowering therapy; avoid with implanted electronic devices.
Monitoring
- HbA1c every 90 days until target
- Renal function and albuminuria annually
- Hypoglycemia review at each medication change
Go deeper
iDetection of an exposure does not establish that it caused a disease. This platform separates exposure, association, plausible mechanism, clinical evidence and demonstrated causation.